News & Events

• November 1, 2018
  

  C-Path Seeking Proposals for Qualitative Research and Preparation of Initial Briefing Package for Two COA Tools Documenting Treatment Benefit in Pediatric Asthma Patients

• May 7, 2018
  

  C-Path Receives COA Qualification from FDA for the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ)

  TUCSON, Ariz. – May 7, 2018 — Critical Path Institute‘s (C-Path) Patient-Reported Outcome (PRO) Consortium announces its second clinical outcome assessment (COA) qualification from the US Food and Drug Administration (FDA). The qualification of the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) for exploratory use represents another major milestone for the PRO Consortium and, specifically,...
• December 18, 2017
  

  C-Path receives COA qualification from FDA for the Symptoms of Major Depressive Disorder Scale (SMDDS)

      Tucson, AZ – December 18, 2017  Critical Path Institute‘s (C-Path) Patient-Reported Outcome (PRO) Consortium announces its first clinical outcome assessment (COA) qualification from the US Food and Drug Administration (FDA) for the Symptoms of Major Depressive Disorder Scale (SMDDS). This qualification of the SMDDS for exploratory use represents a major milestone for the...
• October 9, 2017
  

  Critical Path Innovation Meeting

  On September 14, 2017, Critical Path Institute’s (C-Path) Patient-Reported Outcome (PRO) Consortium and Electronic Patient-Reported Outcome (ePRO) Consortium participated in a Critical Path Innovation Meeting (CPIM) at the U.S Food and Drug Administration’s (FDA) White Oak campus in Silver Spring, MD.  As stated on FDA’s website, the goals for CPIMs are “to discuss a methodology...